Imfinzi Plus Imjudo Shows Significant Five-Year Survival Improvement in Unresectable Liver Cancer
September 16th 2024Data from the Phase III HIMALAYA trial found the combination of Imfinzi plus Imjudo reduced the risk of death by 24% compared to sorafenib in patients with unresectable hepatocellular carcinoma.
Plozasiran Reduces Triglycerides, Pancreatitis Risk in Persistent Chylomicronemia
September 3rd 2024The first-in-class, investigational RNA interference drug plozasiran was found to lower triglyceride levels and incidence of pancreatitis compared to placebo in patients with persistent chylomicronemia, including patients with familial chylomicronemia syndrome.
OASIS Trials Show Efficacy of Elinzanetant in Reducing Hot Flashes in Postmenopausal Individuals
August 26th 2024Elinzanetant was found to significantly lower the frequency and severity of moderate to severe vasomotor symptoms with statistically significant improvements in sleep disturbances and menopause-related quality of life.
Study Shows Infusion of Amino Acids Reduces Risk of Acute Kidney Injury Following Cardiac Surgery
August 23rd 2024Mild or moderate acute kidney injury has been linked to increased morbidity and mortality, with a greater risk of chronic kidney disease in patients who undergo cardiac surgery with cardiopulmonary bypass.
Welireg Shows Survival Advantage Over Everolimus Treating Advanced Clear-Cell Renal Cell Carcinoma
August 22nd 2024A higher percentage of patients with advanced clear-cell renal cell carcinoma administered Welireg were alive and without disease progression compared to everolimus at 12 and 18 months.
Clinical Study Investigates 'Obesity Paradox' in Treatment of Non-Small Cell Lung Cancer
August 5th 2024Multiple observational studies have shown that patients with cancer and a higher body mass index who were administered chemotherapy experienced improved survival compared to patients with normal body weight.